Observational studyJornal brasileiro de nefrologia
Renal outcomes in the long-term follow-up of lupus nephritis.
Observational study in Jornal brasileiro de nefrologia. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Rituximab as Rescue or Add-On Therapy for Relapsing or Refractory Lupus Nephritis: A Systematic Review and Meta-Analysis.Clinical and translational science · 2026Pooled it
- Kidney Biopsy and Prognosis in Lupus Nephritis: Histological Predictors of Renal Outcome-A Narrative Review.Medicina (Kaunas, Lithuania) · 2026Review
- Beyond the trial: a single-center retrospective review of real-world lupus nephritis management and outcomes.Frontiers in medicine · 2026Article
- Serum RNASE1 as a biomarker for disease activity and lupus nephritis in systemic lupus erythematosus.Frontiers in immunology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionLupus nephritis (LN) is one of the most common and serious manifestations of systemic lupus erythe-matosus (SLE) and is recognized as the strongest predictor of poor prognosis. This study aims to analyze demographic characteristics, clinicopathological corre-lations, and risk factors associated with renal outcomes in a long-term follow-up of patients with LN.
methodThis is a retrospective observational cohort study from 112 biopsy-proven LN patients, followed from July 1985 to August 2015. We have evaluated risk factors associated with renal impairment (doubling of serum creatinine), end-stage renal disease (ESRD, eGFR <15 mL/min) and cumulative renal damage using the Systemic Lupus International Collaborating Clinics/ACR Damage Index (SDI).
resultsThe median time of follow-up was 8.3 years. Class IV LN predominated (64.3%), alone or in combination. There was a statistically significant increase in the renal score of SDI between 5 and 10 years of follow-up. In the multivariate analysis, final SDI correlated with initial eGFR <75 mL/min (p < 0.001) and proteinuria >3.5 g/24 h during the course of the disease (p < 0.001), overcoming parameters identified in uni-variate analysis as using cyclophosphamide (p = 0.010) and not using antimalarials (p = 0.003); 13.4% of the patients progressed to renal function impairment, and 11.6% to ESRD. DISCUSSION: Accumulated renal damage by SDI was a frequent finding. The main determinants of renal outcome were baseline eGFR <75 mL/min and proteinuria >3.5 g/24 h during follow-up. Thus, early diagnosis and better management of LN, especially in case of high levels of proteinuria, may help improve prognosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.